EFG Asset Management North America Corp. Sells 31,595 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

EFG Asset Management North America Corp. cut its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 8.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 322,734 shares of the company’s stock after selling 31,595 shares during the period. EFG Asset Management North America Corp.’s holdings in Roivant Sciences were worth $3,820,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ROIV. Natixis Advisors LLC increased its holdings in Roivant Sciences by 8.3% during the 3rd quarter. Natixis Advisors LLC now owns 153,717 shares of the company’s stock worth $1,774,000 after acquiring an additional 11,726 shares during the period. Swiss National Bank grew its position in shares of Roivant Sciences by 1.0% during the 3rd quarter. Swiss National Bank now owns 721,046 shares of the company’s stock valued at $8,321,000 after purchasing an additional 6,900 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Roivant Sciences by 30.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,767,412 shares of the company’s stock worth $31,936,000 after purchasing an additional 646,627 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Roivant Sciences by 13.3% in the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock worth $45,147,000 after buying an additional 458,601 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Roivant Sciences by 10.8% in the third quarter. The Manufacturers Life Insurance Company now owns 356,600 shares of the company’s stock worth $4,115,000 after buying an additional 34,641 shares in the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Trading Up 0.4 %

Shares of ROIV opened at $10.83 on Tuesday. The company has a market cap of $7.73 billion, a price-to-earnings ratio of -72.20 and a beta of 1.26. The business’s fifty day simple moving average is $10.79 and its two-hundred day simple moving average is $11.45. Roivant Sciences Ltd. has a 12 month low of $9.93 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, research analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Insider Activity

In other news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business’s stock in a transaction on Monday, January 13th. The stock was acquired at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eric Venker sold 176,900 shares of the company’s stock in a transaction dated Friday, December 27th. The shares were sold at an average price of $11.82, for a total transaction of $2,090,958.00. Following the sale, the chief operating officer now directly owns 668,680 shares of the company’s stock, valued at $7,903,797.60. The trade was a 20.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,439,640 shares of company stock valued at $27,451,035 in the last 90 days. 7.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ROIV has been the subject of several research reports. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $18.08.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.